Pelabresib Market Summary

Key Factors Driving Pelabresib Growth

1. Large Unmet Need in Frontline Myelofibrosis

Myelofibrosis is a chronic myeloproliferative neoplasm characterized by progressive bone marrow fibrosis, splenomegaly, anemia, and debilitating constitutional symptoms. Current first-line treatment with ruxolitinib provides symptom relief but does not adequately modify disease biology for many patients. Pelabresib is designed to be used in combination with ruxolitinib to improve clinical outcomes beyond JAK inhibitor monotherapy, addressing a significant unmet need in newly diagnosed, JAK inhibitor-naïve patients.

2. Positive Phase III MANIFEST-2 Results Demonstrate Superior Spleen Responses

The pivotal Phase III MANIFEST-2 trial enrolled 430 JAK inhibitor-naïve patients, making it one of the largest myelofibrosis studies conducted to date. The study met its primary endpoint, with 65.9% (approximately 66%) of patients receiving pelabresib plus ruxolitinib achieving ≥35% spleen volume reduction (SVR35) at Week 24 compared with 35.2% for placebo plus ruxolitinib (p<0.001), nearly doubling the response rate. Although the overall key symptom endpoint (TSS50) was not statistically significant, meaningful improvements were observed in predefined intermediate-risk patients.

3. Disease-Modifying Activity Beyond Symptom Control

Unlike therapies that primarily reduce splenomegaly and symptoms, pelabresib has demonstrated improvements across several hallmarks of myelofibrosis. MANIFEST-2 showed evidence of:

• Improved anemia, including higher hemoglobin response rates and fewer transfusion requirements.
• Improvement in bone marrow fibrosis in a greater proportion of patients.
• Favorable safety with no unexpected adverse events.

These findings suggest pelabresib may provide disease-modifying benefits rather than symptomatic control alone, an important differentiator in the MF treatment landscape.

4. Novel BET Inhibition Mechanism Complements JAK Inhibition

Pelabresib inhibits BET proteins (BRD2/3/4), reducing transcription of genes involved in inflammation, fibrosis, and malignant hematopoiesis. This mechanism complements JAK1/2 inhibition by ruxolitinib, targeting both inflammatory signaling and the underlying biology of myelofibrosis. The combination strategy has the potential to improve durability of response and alter disease progression more effectively than JAK inhibition alone.

5. Backing by Novartis Strengthens Global Commercial Potential

Following its acquisition of MorphoSys, Novartis gained global rights to pelabresib, adding it to its hematology portfolio alongside Jakavi/Jakafi (ruxolitinib). Novartis possesses extensive commercial infrastructure in hematologic malignancies, established relationships with hematologists, and global regulatory expertise, which could facilitate broad market adoption if pelabresib receives regulatory approval. However, following review of longer-term MANIFEST-2 data, Novartis indicated that additional follow-up and potentially further clinical studies may be required to define the regulatory pathway.

Pelabresib Recent Developments

In February 2024, Novartis announced that it entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG, a Germany-based, global biopharmaceutical company developing innovative medicines in oncology. The acquisition, which is subject to customary closing conditions, including a minimum acceptance threshold of 65% of outstanding shares tendered in the takeover offer and regulatory approvals, further expands and complements Novartis pipeline in oncology, one of its priority therapeutic areas, while also enhancing Novartis global footprint in hematology.

“Pelabresib Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Pelabresib for potential indication like Myelofibrosis, Essential thrombocythaemia, Leukaemia, Myelodysplastic syndromes, and Haematological malignancies in the 7MM. A detailed picture of Pelabresib’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Pelabresib for potential indications. The Pelabresib market report provides insights about Pelabresib’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Pelabresib performance, future market assessments inclusive of the Pelabresib market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Pelabresib sales forecasts, along with factors driving its market.

Pelabresib Drug Summary

Pelabresib is an investigational, orally administered small-molecule bromodomain and extraterminal (BET) protein inhibitor being developed by MorphoSys AG (now part of Novartis) for the treatment of hematologic malignancies, particularly Myelofibrosis. Pelabresib selectively inhibits the BET family of epigenetic reader proteins (BRD2, BRD3, BRD4, and BRDT), disrupting the transcription of genes involved in inflammation, fibrosis, and malignant cell proliferation, including NF-κB- and MYC-regulated pathways. Through this mechanism, the drug aims to reduce bone marrow fibrosis, suppress pro-inflammatory cytokine signaling, improve hematopoiesis, and alleviate constitutional symptoms associated with myelofibrosis. Clinical studies have demonstrated encouraging improvements in spleen volume reduction, symptom burden, anemia, and bone marrow fibrosis, particularly when pelabresib is combined with Ruxolitinib. The global Phase III MANIFEST-2 trial met its primary endpoint of superior spleen volume reduction versus ruxolitinib alone in treatment-naïve patients with myelofibrosis, supporting pelabresib's potential as a first-line combination therapy. Although the drug has not yet received regulatory approval, it remains one of the most advanced BET inhibitors in late-stage clinical development for myelofibrosis. The report provides Pelabresib’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Pelabresib Market Report

The report provides insights into:

• A comprehensive product overview including the Pelabresib MoA, description, dosage and administration, research and development activities in potential indication like Myelofibrosis, Essential thrombocythaemia, Leukaemia, Myelodysplastic syndromes, and Haematological malignancies.
• Elaborated details on Pelabresib regulatory milestones and other development activities have been provided in Pelabresib market report.
• The report also highlights Pelabresib‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Pelabresib market report also covers the patents information, generic entry and impact on cost cut.
• The Pelabresib market report contains current and forecasted Pelabresib sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Pelabresib market report also features the SWOT analysis with analyst views for Pelabresib in potential indications.

Methodology

The Pelabresib market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Pelabresib Analytical Perspective by DelveInsight

• In-depth Pelabresib Market Assessment

This Pelabresib sales market forecast report provides a detailed market assessment of Pelabresib for potential indication like Myelofibrosis, Essential thrombocythaemia, Leukaemia, Myelodysplastic syndromes, and Haematological malignancies in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Pelabresib sales data uptil 2034.

• Pelabresib Clinical Assessment

The Pelabresib market report provides the clinical trials information of Pelabresib for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Pelabresib Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Pelabresib Market Potential & Revenue Forecast

• Projected market size for the Pelabresib and its key indications
• Estimated Pelabresib sales potential (Pelabresib peak sales forecasts)
• Pelabresib Pricing strategies and reimbursement landscape

Pelabresib Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Pelabresib Market positioning compared to existing treatments
• Pelabresib Strengths & weaknesses relative to competitors

Pelabresib Regulatory & Commercial Milestones

• Pelabresib Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Pelabresib Clinical Differentiation

• Pelabresib Efficacy & safety advantages over existing drugs
• Pelabresib Unique selling points

Pelabresib Market Report Highlights

• In the coming years, the Pelabresib market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Pelabresib companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Pelabresib’s dominance.
• Other emerging products for Myelofibrosis, Essential thrombocythaemia, Leukaemia, Myelodysplastic syndromes, and Haematological malignancies are expected to give tough market competition to Pelabresib and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Pelabresib in potential indications.
• Analyse Pelabresib cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Pelabresib sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Pelabresib in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Pelabresib? How strong is Pelabresib’s clinical and commercial performance?
• What is Pelabresib’s clinical trial status in each individual indications such as Myelofibrosis, Essential thrombocythaemia, Leukaemia, Myelodysplastic syndromes, and Haematological malignancies and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Pelabresib Manufacturers?
• What are the key designations that have been granted to Pelabresib for potential indications? How are they going to impact Pelabresib’s penetration in various geographies?
• What is the current and forecasted Pelabresib market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Pelabresib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Pelabresib for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Pelabresib? What is the duration of therapy and what are the geographical variations in cost per patient?